Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
“We welcome Todd to the team. He brings a proven track record and
significant experience in sales, marketing and market access that will
be integral as we prepare Kala to become a commercial organization,”
said
Todd is a biopharmaceutical executive with 23 years of experience
spanning from ultra-rare orphan diseases to large primary care
conditions. Prior to joining
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, that
involve substantial risks and uncertainties including statements
regarding the development and regulatory status of the company's product
candidates, including INVELTYSTM (KPI-121 1%) for the
treatment of inflammation and pain following ocular surgery and KPI-121
0.25% for the temporary relief of the signs and symptoms of dry eye
disease. All statements, other than statements of historical facts,
contained in this press release, including statements regarding the
Company’s strategy, future operations, future financial position, future
revenue, projected costs, prospects, plans and objectives of management,
are forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. The Company may not actually achieve the plans,
intentions or expectations disclosed in its forward-looking statements,
and you should not place undue reliance on such forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements as a result of various risks and uncertainties including, but
not limited to: whether our submitted NDA for INVELTYS will be accepted
for filing and approved; uncertainties inherent in the availability and
timing of data from ongoing clinical trials; whether the data from our
Phase 3 clinical trials of KPI-121 0.25% will warrant submission of an
NDA on the timeline expected, or at all, and whether any such NDA would
will be approved; expectations for regulatory approvals to conduct
trials or to market products; whether the Company’s cash resources will
be sufficient to fund the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements; other matters
that could affect the availability or commercial potential of the
Company’s product candidates; and other important factors, any of which
could cause the Company’s actual results to differ from those contained
in the forward-looking statements, discussed in the "Risk Factors"
section of the Company’s most recently filed Quarterly Report on Form
10-Q and other filings the Company makes with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005335/en/
Source:
Investors and Media:
MacDougall Biomedical Communications
Cammy
Duong, 781-591-3443
cduong@macbiocom.com